Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ENTR-601-44 · 2 trials · 1 indication
Safety will be assessed by monitoring adverse events, physical examination, vital signs and clinical laboratory tests.
Safety will be assessed by monitoring adverse events, physical examination, vital signs and clinical laboratory tests.
| Arm | Type | Description |
|---|---|---|
| ENTR-601-44 | EXPERIMENTAL | ENTR-601-44 intravenous infusion every 6 weeks |
| ENTR-601-45 | EXPERIMENTAL | ENTR-601-45 intravenous infusion every 6 weeks |
| Placebo | PLACEBO_COMPARATOR | intravenous infusion every 6 weeks |
| Name | Type | Description |
|---|---|---|
| ENTR-601-44 | DRUG | ENTR-601-44 intravenous infusion |
| ENTR-601-45 | DRUG | ENTR-601-45 intravenous infusion |
| ENTR-601-44 - matching placebo | DRUG | intravenous infusion |
Inclusion Criteria: * Willing and able to provide consent (if at age of majority) or assent (if a minor) * Participant completed clinical study ENTR-601-44-201 or ENTR-601-45-201 * Males who are sexually active with a female partner of childbearing potential must agree to use condoms during sexual ...
ENTR-601-44 is an investigational small molecule being developed for Duchenne Muscular Dystrophy (DMD) in patients amenable to exon 44 skipping. It is designed to target the DMD exon 44 region. The drug is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
ENTR-601-44 targets the DMD exon 44 region of the dystrophin gene. This target is relevant for patients with Duchenne Muscular Dystrophy who have mutations amenable to exon 44 skipping, a strategy intended to restore the reading frame of the dystrophin protein.
ENTR-601-44 is being developed by Entrada Therapeutics, Inc., a biopharmaceutical company publicly traded under the ticker symbol TRDA. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for Duchenne Muscular Dystrophy.
ENTR-601-44 is in Phase 2 clinical development for Duchenne Muscular Dystrophy. It is an investigational drug, meaning it has not received FDA approval and is still undergoing clinical trials to assess its safety and effectiveness in patients.
ENTR-601-44 is being studied in two clinical trials. NCT07037862 is a Phase 1 study recruiting 24 male participants with DMD amenable to exon 44 skipping. NCT07682129 is a Phase 2 long-term extension study with 80 participants, not yet recruiting. Both are controlled, randomized, and double-blind.
ENTR-601-44 is a distinct investigational drug developed by Entrada Therapeutics. It is part of a class of therapies targeting exon 44 skipping in Duchenne Muscular Dystrophy, but it is not the same as other approved or investigational exon-skipping agents. No alternative names for ENTR-601-44 have been disclosed.